載入中
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
前收盤價
US$4.33
+US$0.13 · +3.10%
盤中時間採用ET。市場資料可能有所延遲。
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
日內區間
目前US$4.33
52週區間
目前US$4.33
盤中時間採用ET。市場資料可能有所延遲。
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.
日內區間
目前US$4.33
52週區間
目前US$4.33
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 200萬 USD | — | 134萬 USD | 270.3萬 USD | 270.3萬 USD |
| 銷貨成本 | 198.7萬 USD | — | — | — | — |
| 毛利 | 1.3萬 USD | — | 134萬 USD | 270.3萬 USD | 270.3萬 USD |
| 研究與開發 | 638.1萬 USD | 632.4萬 USD | 897.1萬 USD | 2763.9萬 USD | 2098.9萬 USD |
| 銷售、一般及管理費用 | 872萬 USD | 645.7萬 USD | 813.8萬 USD | 1566.2萬 USD | 593.7萬 USD |
| 營業費用 | 1510.1萬 USD | 1278.1萬 USD | 1710.9萬 USD | 4330.1萬 USD | 2692.6萬 USD |
| 利息收入 | 237.3萬 USD | 498.3萬 USD | 802.6萬 USD | 357.3萬 USD | 34.7萬 USD |
| 利息支出 | — | 85.3萬 USD | 358萬 USD | — | — |
| 折舊和攤銷 | 12.1萬 USD | 19.3萬 USD | 19.6萬 USD | 5.8萬 USD | 7.7萬 USD |
| 營業利益 | −1508.8萬 USD | −1278.1萬 USD | −1576.9萬 USD | −4059.8萬 USD | −2422.3萬 USD |
| 淨利 | 6405萬 USD | −1906萬 USD | 552.5萬 USD | −3776.4萬 USD | −2223.8萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
